Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Opinion|Videos|August 9, 2024

The Harms and Consequences of Untreated PTSD

Author(s)John J. Miller, MD

John J. Miller, MD, discusses the risks of untreated PTSD and the importance of implementing more therapeutic tools into treatment paradigms.

Episodes in this series

John J. Miller, MD

EP. 1 The Evolution of PTSD Diagnosis and Treatment

John J. Miller, MD

EP. 2 MDMA-Assisted Therapy: Providing the Brain With a Necessary Boost

John J. Miller, MD

EP. 3 The Challenges of PTSD Symptom Clusters

John J. Miller, MD

EP. 4 Unmet Needs and the PTSD Treatment Pipeline

John J. Miller, MD

EP. 5 Do No Harm: Providing Guardrails for Effective PTSD Treatments

John J. Miller, MD

EP. 6 The Harms and Consequences of Untreated PTSD

PTSD

EP. 7 5 Key Take-Aways About PTSD Treatment: A Closer Look at MDMA

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

psychedelic

Podcast: Exploring Entactogens With Hiroe Imai Hu, DO, and James W. Murrough, MD, PhD

ByJenessa Johnston, PhD,Hiroe Hu, DO,James Murrough, MD, PhD

August 13th 2026

Entactogens as a New Frontier for Mood and Anxiety Disorders: A Conversation With Hiroe Imai Hu, DO, and James W. Murrough, MD, PhD

ByJenessa Johnston, PhD

August 13th 2026

trauma

Podcast: Navigating Trauma, Transformations, and Truth With Emily Lafferman, MD

ByFrank A. Clark, MD,Emily Lafferman, MD

August 5th 2026

concussion

When Brain Injury and Mental Health Look the Same: The Diagnostic Challenge of Concussion Recovery

ByBrandee Grate-Perry, MSW, LCSWA,Mena Mirhom, MD, FAPA

July 27th 2026

brain electric

New Positive Data From Largest Real-World Study of Deep TMS in Patients With Comorbid PTSD and MDD

June 29th 2026

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

Kratom Component in Clinical Trial for Opioid Use Disorder

NIDA Awards PleoPharma $6.5 Million Grant to Advance Phase 3 Trial of PP-01 for Cannabis Use Disorder

Why Cultural Context Matters in Psychiatric Assessment

FDA Feedback Paves Way for New IND Filing for PT00114 in Generalized Anxiety Disorder

Brain Function Biomarker Testing In Psychiatry With Universal Brain EEG